• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis

by MM360 Staff | Dec 8, 2025 | Publications

Blood Cancer J. 2025 Dec 6;15(1):212. doi: 10.1038/s41408-025-01413-7. ABSTRACT Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet...

Addition of daratumumab to standard triplet regimens achieved better survival in newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials

by MM360 Staff | Nov 18, 2025 | Publications

Front Oncol. 2025 Oct 30;15:1619115. doi: 10.3389/fonc.2025.1619115. eCollection 2025. ABSTRACT BACKGROUND: Triplet regimens, such as bortezomib-lenalidomide-dexamethasone (VRd) and bortezomib-melphalan-prednisone (VMP), were standard treatments for newly diagnosed...

Inflammatory markers from routine blood tests predict survival in multiple myeloma: a Systematic Review and meta-analysis

by MM360 Staff | Nov 18, 2025 | Publications

Front Immunol. 2025 Oct 30;16:1669878. doi: 10.3389/fimmu.2025.1669878. eCollection 2025. ABSTRACT BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy marked by abnormal plasma cell proliferation. Inflammatory indices derived from routine blood...

The challenge of non-transplant eligible, newly diagnosed multiple myeloma

by MM360 Staff | Nov 15, 2025 | Publications

Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3. ABSTRACT Eligibility for autologous transplantation is a key factor for tailoring treatment decisions in patients with newly-diagnosed multiple myeloma. For non-eligible...

Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials

by MM360 Staff | Nov 10, 2025 | Publications

J Natl Cancer Inst. 2025 Nov 9:djaf326. doi: 10.1093/jnci/djaf326. Online ahead of print. ABSTRACT INTRODUCTION: Although myeloma represents a key success story in oncology, some drugs have failed to meet primary endpoints in randomized controlled trials (RCTs),...

Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review

by MM360 Staff | Nov 2, 2025 | Publications

Chin Med J (Engl). 2025 Oct 31. doi: 10.1097/CM9.0000000000003832. Online ahead of print. NO ABSTRACT PMID:41173804 | DOI:10.1097/CM9.0000000000003832
« Older Entries
Next Entries »

Recent Content

  • Scientists find new way to kill treatment-resistant myeloma cells
  • Phase 3 blood cancer vaccine trial moves toward final analysis
  • Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review
  • MajesTEC results with teclistamab in relapsed and/or refractory multiple myeloma
  • Phase 3 trial testing if oral pill can stop pancreatic cancer from returning
  • (no title)
  • Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
  • CAR T-cells in multiple myeloma: the race to the start line
  • Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia
  • Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT